gene therapy sarepta - Search News

Order byBest matchMost fresh

News

Sarepta shares crash

· 22h · on MSN

Sarepta Stock Plunges After Death of Second Patient Receiving Its Gene Therapy

Sarepta Therapeutics stock plummeted Monday after the company said a second patient receiving its gene therapy died from liver failure, raising serious questions on the drug’s outlook.Shares fell 40% to $21.

Continue reading

· 16h · on MSN

Sarepta shares crash as second patient dies after receiving its gene therapy

· 17h · on MSN

Second patient death reported with gene therapy for muscular dystrophy

After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry

Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other ...

1d

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and ...

Managed Healthcare Executive22h

Sarepta Stops Shipments of Elevidys For Non-Ambulatory DMD Patients

A second patient with Duchenne muscular dystrophy has died from acute liver failure after receiving the gene therapy Elevidys ...

Pharmalittle: We’re reading about a Lilly deal, a gene therapy shock for Duchenne families, and more

In today's Pharmalittle roundup, we're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results